Monoamine oxidase

Monoamine Oxidase Type-B (MAO-B) Inhibitors for 7 MM: Market Size, Target Population, Competitive Landscape & Forecasts, 2034 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 6, 2024
Health, Pharmaceutical, Therapy, Key, Inflation, Competitive landscape, Monoamine oxidase, Physician, News, Opinion, SWOT, EU4, Inhibitor, Safety, HTA, Patient, Disease, Drug, Mutation, Pharmaceutical industry

The "Monoamine Oxidase Type-B (MAO-B) Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Monoamine Oxidase Type-B (MAO-B) Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.
  • The Monoamine Oxidase Type-B (MAO-B) Inhibitors market report provides insights around existing treatment practices in patients with Monoamine Oxidase Type-B (MAO-B) Inhibitors, approved (if any) and emerging Monoamine Oxidase Type-B (MAO-B) Inhibitors, market share of individual therapies, patient pool eligible for treatment with Monoamine Oxidase Type-B (MAO-B) Inhibitors, along with current and forecasted 7MM Monoamine Oxidase Type-B (MAO-B) Inhibitors market size from 2020-2034 by therapies and by indication.
  • This section will include details on changing Monoamine Oxidase Type-B (MAO-B) Inhibitors market dynamics post initiation of clinical development activities of the inhibitor.
  • The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Monoamine Oxidase Type-B (MAO-B) Inhibitors.

Terran Biosciences announces publication of PCT patent applications covering orally active forms of DMT and 5-MeO-DMT and long-acting MDMA

Retrieved on: 
Friday, February 3, 2023
Patent, Brain, MDMA, Therapy, Patient, MAO, Liver, Monoamine oxidase, Vomiting, DMT, Prodrug, PCT, Nausea, Invention, Terran, Blood pressure, Pharmacokinetics, Pharmaceutical industry

NEW YORK, Feb. 3, 2023 /PRNewswire/ -- Terran Biosciences ("Terran"), a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, has announced the publication of PCT patent applications covering novel prodrugs of DMT, 5-MeO-DMT, and MDMA.

Key Points: 
  • NEW YORK, Feb. 3, 2023 /PRNewswire/ -- Terran Biosciences ("Terran"), a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, has announced the publication of PCT patent applications covering novel prodrugs of DMT, 5-MeO-DMT, and MDMA.
  • These applications highlight new data from animal studies demonstrating that DMT and 5-MeO-DMT can be made orally active through Terran's proprietary prodrug approach.
  • With this new data from animal models, Terran believes these prodrugs may represent the first known examples of orally active forms of DMT and 5-MeO-DMT.
  • Terran's MDMA approach is described in detail in the PCT patent application: "3,4-Methylenedioxymethamphetamine and related psychedelics and uses thereof" (WO/2023/283373).

Core One Labs Announces Successful Proof-of-Concept for Biosynthetic N-methyltryptamine (NMT)

Retrieved on: 
Thursday, March 3, 2022
OTC, Core, Family, Patient, Corona Labs Inc., Research, WKN, Monoamine oxidase, Tryptamine, LABS, Biotechnology, DNA, Enzyme, Database, Mouth, Bacteria, CSE, Psilocybe, Company, MAOI, Patent, CGMP, Psilocybin, Nature, MMT, Technology, Intellectual property, NMT, R, N-Methyltryptamine, GLOBE, Animal, Fine chemical, Pharmaceutical industry

The analog compounds, being synthetic in nature, have the potential to be more effective and safer than the natural compounds.

Key Points: 
  • The analog compounds, being synthetic in nature, have the potential to be more effective and safer than the natural compounds.
  • Core Ones proprietary Recombinant Production System aims to reshape the psychedelic industry by providing cGMP compliant biosynthetic psychedelic compounds and analogs in large volumes and quicker turnaround time.
  • Such a breakthrough marks Core One Labs as a major player in the psychedelic sector and makes its product portfolio unrivaled amongst its competitors.
  • 1 Foye's principles of medicinal chemistry By William O. Foye, Thomas L. Lemke, David A. Williams
    ABOUT CORE ONE LABS INC.

Core One Labs’ Files Milestone Patent for Protection of its Recombinant Production System for Optimized Biosynthetic N-methyltryptamine (NMT)

Retrieved on: 
Monday, February 21, 2022
GLOBE, CSE, Patent, Tryptamine, LABS, Intellectual property, Mouth, Industry, Company, Database, Blonder-Tongue Labs., Inc. v. University of Ill. Foundation, OTC, Psychedelic drug, Psilocybin, NMT, API, Bacteria, Monoamine oxidase, Biotechnology, United States Patent and Trademark Office, Leadership, WKN, R, Patient, Technology, CEO, Research, CGMP, MMT, MAOI, Fine chemical, Pharmaceutical industry, System

N-Methyltryptamine is a member of tryptamines and is an organic compound known to producepsychoactive effects when combinedwith amonoamine oxidase A inhibitor (MAOI).1

Key Points: 
  • N-Methyltryptamine is a member of tryptamines and is an organic compound known to producepsychoactive effects when combinedwith amonoamine oxidase A inhibitor (MAOI).1
    The patent entitled Production of Psychedelic Compounds protects Core Ones novel proprietary production system.
  • Filing this patent is an important milestone for the company since it allows us to protect our intellectual property against potential competitors.
  • The patent provides a broad array of strategies useful for making psychedelic compounds enabling Core One to diversify its product portfolio, stated Dr. Bob Hancock, CEO of Vocan Biotechnologies.
  • Core One also holds an interest in medical clinics which maintain a combined database of over 275,000 patients.

MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases

Retrieved on: 
Tuesday, August 10, 2021
Biotechnology, Pharmaceutical, Health, Clinical Trials, Addiction, Intention, Inflammation, Patent, Epilepsy, CB2, Longevity, Enzyme, Pain, Cytokine, Chronic pain, Cocaine, Neurodegeneration, Anxiety, Human, Forward-looking statement, USPTO, Methamphetamine, Seizure, Cannabidiol, COVID-19, Ageing, Compte rendu, Nasdaq, Degenerative disease, Monoamine oxidase, FDA, Treatment, Pharmaceutical industry

11,085,047 titled Synthetic Cannabinoid Compounds for the Treatment of Substance Addiction and Other Disorders.

Key Points: 
  • 11,085,047 titled Synthetic Cannabinoid Compounds for the Treatment of Substance Addiction and Other Disorders.
  • The patent protects the Companys drug candidate Supera-CBD , a synthetic cannabidiol derivative that targets cannabinoid receptor type 2 (CB2) for the treatment of neuroinflammatory and neurodegenerative diseases.
  • This first patent for Supera-CBD will support our discovery efforts as we move forward with this platform as a major focus for our Company.
  • MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) is a clinical stage pharmaceutical company committed to extending healthy lifespan in humans by focusing on developing two therapeutic platforms.

MyMD Pharmaceuticals Subsidiary Oravax Medical Preparing to Commence Clinical Trials for Oral COVID-19 Vaccine

Retrieved on: 
Tuesday, August 10, 2021
Infectious Diseases, Pharmaceutical, Health, Clinical Trials, Protein, Intention, Oramed, Longevity, CB2, Patient, Cytokine, Ownership, Human, Mutation, Death, Forward-looking statement, Virus, Cannabidiol, COVID-19, SARS, Ageing, Compte rendu, VLP, Board, Depression, Degenerative disease, Monoamine oxidase, FDA, Pharmaceutical industry, Oravax Medical, MyMD Pharmaceuticals, Inc., ORAVAX MEDICAL, MYMD PHARMACEUTICALS, INC.

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (MyMD or the Company), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today reported that its subsidiary Oravax Medical Inc. (Oravax), partially owned with its majority partner Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (Oramed), is preparing to commence clinical trials for its oral COVID-19 vaccine, first in Israel, then in additional clinical sites internationally.

Key Points: 
  • MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (MyMD or the Company), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today reported that its subsidiary Oravax Medical Inc. (Oravax), partially owned with its majority partner Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (Oramed), is preparing to commence clinical trials for its oral COVID-19 vaccine, first in Israel, then in additional clinical sites internationally.
  • Oramed and MYMD are currently evaluating several options with respect to their interest in Oravax including a potential distribution of Oravax shares to both Oramed and MYMD shareholders.
  • The potential spin-off of Oravax could be beneficial to MyMD shareholders through our ownership stake and due to Oravaxs strong position in the public markets as an oral vaccine developer, said Josh Silverman, Chairman of the Board of MyMD Pharmaceuticals.
  • Oravax combines cutting edge vaccine technology acquired from Premas Biotech and the proprietary POD oral delivery technology of Oramed Pharmaceuticals.

MyMD Pharmaceuticals’ Lead Compound MYMD-1 Shown to Suppress a Major Cause of Death in COVID-19 in Human Cell Study

Retrieved on: 
Thursday, August 5, 2021
Stem Cells, Biotechnology, Health, General Health, Pharmaceutical, Mental Health, Other Science, Research, Infectious Diseases, Science, Clinical Trials, Clinical trial, Research, Cytokine, Ageing, Degenerative disease, Compte rendu, Human, Tumor necrosis factor, CB2, Tissue, Autoimmunity, Prevalence, Patient, Phase II, COVID-19, Depression, Monoamine oxidase, Intention, Immune system, Food and Drug Administration, Sarcopenia, Longevity, Nasdaq, Death, Coronavirus, Cannabidiol, Frailty, Forward-looking statement, Pharmaceutical industry

MYMD-1 regulates the immuno-metabolic system by modulating numerous pro-inflammatory cell signaling molecules called cytokines.

Key Points: 
  • MYMD-1 regulates the immuno-metabolic system by modulating numerous pro-inflammatory cell signaling molecules called cytokines.
  • Along with our focus on extending healthy lifespan, treatment for COVID-19-related complications is now a cornerstone of our clinical development plan for MYMD-1.
  • According to MyMD Chief Scientific Officer Adam Kaplin, M.D., Ph.D., The importance of our upcoming Phase 2 trial cant be overstated.
  • MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) is a clinical stage pharmaceutical company committed to extending healthy lifespan in humans by focusing on developing two therapeutic platforms.

Monoamine Oxidase Inhibitors Pipeline Insight Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 5, 2021
Health, Pharmaceutical, Psychoactive drugs, Monoamine oxidase inhibitors, Drugs, Amphetamine, Antidepressants, Hydrazines, Reversible inhibitors of MAO-A, Monoamine neurotransmitter, Monoamine oxidase, Tetrindole, Luteusin A

The "Monoamine Oxidase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Monoamine Oxidase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Monoamine Oxidase Inhibitors - Pipeline Insight, 2021" report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Monoamine Oxidase Inhibitors pipeline landscape.
  • This segment of the report provides insights about the different Monoamine Oxidase Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • Monoamine Oxidase Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Sun Pharma Launches Drizalma Sprinkle in the U.S.

Retrieved on: 
Wednesday, October 16, 2019
Biotechnology, FDA, Mental health, Health, Pharmaceutical, Chemical compounds, RTT, Organic compounds, Drugs, Monoamine oxidase inhibitor, Duloxetine, Linezolid, Serotonin syndrome, Monoamine oxidase, Paroxetine, Serotonin, Methylene blue

Drizalma Sprinkle is the first and only FDA-approved formulation of duloxetine that can be swallowed whole, sprinkled on applesauce or administered via nasogastric tube.

Key Points: 
  • Drizalma Sprinkle is the first and only FDA-approved formulation of duloxetine that can be swallowed whole, sprinkled on applesauce or administered via nasogastric tube.
  • Serotonin syndrome and MAOIs: Do not use MAOIs intended to treat psychiatric disorders with Drizalma Sprinkle or within 5 days of stopping treatment with Drizalma Sprinkle.
  • In addition, do not start Drizalma Sprinkle in a patient who is being treated with linezolid or intravenous methylene blue.
  • Drizalma Sprinkle should not be prescribed to patients with substantial alcohol use or evidence of chronic liver disease.

Kindred Biosciences to Present at Cantor Global Healthcare Conference and Ladenburg Thalmann 2018 Healthcare Conference

Retrieved on: 
Monday, September 17, 2018
Neurochemistry, Anxiolytics, Antidepressants, Noradrenergic and specific serotonergic antidepressants, Serotonin antagonists, Tetracyclic antidepressants, Neuroscience, Monoamine oxidase inhibitor, Mirtazapine, Monoamine oxidase

Do not use in cats with a known hypersensitivity to mirtazapine or any of the excipients or in cats treated with monoamine oxidase inhibitors (MAOIs).

Key Points: 
  • Do not use in cats with a known hypersensitivity to mirtazapine or any of the excipients or in cats treated with monoamine oxidase inhibitors (MAOIs).
  • Kindred Biosciences is a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets.
  • Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy.
  • KindredBio's first approved drug is Mirataz (mirtazapine transdermal ointment) for the management of weight loss in cats.